Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 4, 2007, Pages 410-415

  Staško, Ján ^a   Galajda, Peter ^a   Ivanková, Jela ^a   Hollý, Pavol ^a   Rozborilová, Eva ^a   Kubisz, Peter ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

Thromboglobulin; Hemodialysis; Platelet factor 4; Recombinant human erythropoietin; Soluble P selectin

Indexed keywords

BETA THROMBOGLOBULIN; CUPROPHANE; PADGEM PROTEIN; RECOMBINANT ERYTHROPOIETIN; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BLOOD ANALYSIS; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; THROMBOSIS; ADOLESCENT; ANEMIA; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SOLUBILITY;

ADOLESCENT; ADULT; AGED; ANEMIA; CASE-CONTROL STUDIES; EPOETIN ALFA; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; RENAL DIALYSIS; SOLUBILITY;

EID: 35748980591     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607303348     Document Type: Article

References (34)

1. Polgar J., Matuskova J., Wagner DD The P selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005 ; 3: 1590.
2. McEver RP Adhesive interactions of leucocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001 ; 86: 746.
3. Frenette P., Johnson R., Hynes R., et al. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial sP-selectin. Proc Natl Acad Sci USA. 1995 ; 92: 7450.
4. Blann AD, Lip Gyh. Hypothesis: Is soluble P-selectin a new marker of platelet activation. Atherosclerosis. 1997 ; 128: 135.
5. Nadar SK, Lip Gyh, Blann AD Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke: The West Birmingham stroke project. Thromb Haemost. 2004 ; 92: 1342.
6. Tan K, Tayebjee M, Lynd C, Blann AD, et al. Platelet microparticles and soluble P selectin in peripheral artery disease: Relationship to extent of disease and platelet activation markers. Ann Med. 2005;37:61.
7. Nurden AT Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost. 2005 ; 3: 1773.
8. Sirolli V., Strizzi L., Di Sante S., et al. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Haemost. 2001 ; 86: 834.
9. Bonomini M., Dottori S., Amoroso L., et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uraemia. J Thromb Haemost. 2004 ; 2: 1275.
10. López JA, Del Conde I, Shrimpton CN Receptors, rafts, and microvesicles in thrombosis and inflammation. J Thromb Haemost. 2005 ; 3: 1737.
11. Tassies D., Reverter JC, Cases A., et al. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: Association with early improvement in platelet function. Am J Hematol. 1998 ; 59: 105.
12. Zwaginga JJ Hemodialysis, erythropoietin and megakaryocytopoiesis: Factors in uremic thrombocytopathy and thrombophilia. J Thromb Haemost. 2004 ; 2: 1272.
13. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. European Best Practice Guidelines for Haemodialysis (Part 1): Section III: Biocompatibility. Nephrol Dial Transplant. 2002; 17(suppl 7):32.
14. Bonomini M., Reale M., Santarelli P., et al. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998 ; 79: 399.
15. Musiał K., Zwolinska D., Polak-Jonkisz D., et al. Soluble adhesion molecules in children and young adults on chronic hemodialysis. Pediatr Nephrol. 2004 ; 19: 332.
16. Kawabata K., Nagake Y., Shikata K., et al. Soluble P-selectin is released from activated platelets in vivo during hemodialysis. Nephron. 1998 ; 78: 148.
17. de Sa HM, Freitas LA, Alves VC, et al. Leukocyte, platelet and endothelial activation in patients with acute renal failure treated by intermittent hemodialysis. Am J Nephrol. 2001 ; 21: 264.
18. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J. 1990 ; 300: 573.
19. Tobu M., Iqbal O., Fareed D., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost. 2004 ; 10: 225.
20. Ikegaya N., Yamamoto T., Takeshita A., et al. Elevated erythropoietin receptor and transforming growth factor-β1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. 2000 ; 11: 928.
21. Grandaliano G., Teutonico A., Allegretti A., et al. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney Int. 2003 ; 64: 715.
22. Van Geet C., Van Damme-Lombaerts R., Vanrusselt M., et al. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: Possible link ? Thromb Haemost. 1990 ; 64: 7.
23. Stenver D., Jeppesen L., Nielsen B., et al. The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure. Int J Artif Organs. 1994 ; 17: 141.
24. Bellon JL, Castellanos C., Acevedo L., et al. Measurement of beta-thromboglobulin and platelet factor 4 to follow up patients with artificial heart valves. Semin Thromb Hemost. 1993 ; 19 (suppl 1). 178.
25. Clyne N., Egberg N., Lins LE Effects of hemodialysis and long-term erythropoietin treatment on protein C, and on free and total protein S. Thromb Res. 1995 ; 80: 161.
26. Kappelmayer J., Nagy B. Jr, Miszti-Blasius K., et al. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med. 2 004 ; 42: 475.
27. Barbaux SC, Blankenberg S., Rupprecht HJ, et al. Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1668.
28. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001 ; 103: 491.
29. Kahraman S., Yilmaz R., Kirkpantur A., et al. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology. 2005 ; 10: 264.
30. Malyszko J., Malyszko JS, Mysliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press Res. 2004 ; 27: 71.
31. Seyfert UT, Helmling E., Hauck W., et al. Comparison of blood biocompatibility during haemodialysis with cuprophane and polyacrylonitrile membranes. Nephrol Dial Transplant. 1991 ; 6: 428.
32. Sultan Y., London GM, Goldfarb B., et al. Activation of platelets, coagulation and fibrinolysis in patients on long-term haemodialysis: Influence of cuprophan and polyacrylonitrile membranes. Nephrol Dial Transplant. 1990 ; 5: 362.
33. Ivanovich P., Hammerschmidt E., Quintanilla A., et al. Behaviour of platelets and β-thromboglobulin. Nephrol Dial Transplant. 1993 ; 8 (suppl 2). 15.
34. Sagedal S., Hartmann A., Sundstrøm K., et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant. 2001 ; 16: 987.